sellWeak
Robert Leasure Jr. sold $57k of NOTV
President and CEO at Inotiv, Inc.. 113,297 shares at an average of $0.50, traded Feb 2, 2026, filed Feb 3, 2026.
Warning score
32Value
$57k
113,297 shares
Holdings after
1,273,025
-8% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +7Trade size$57k at market
- 0Share of holdings soldSold 8.2% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001762245-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | SOpen-market sale Common Stock | -113,297 | $0.50 | $57k | 1,273,025 | Feb 3, 2026 |
Related signals
Other insiders at Inotiv, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 17Weak | Inotiv, Inc. | Beth Taylor Chief Financial Officer | $846 2,888 shares | -2% | |
| 10Weak | Inotiv, Inc. | John E Sagartz Chief Strategy Officer | $616 2,119 shares | -0% | |
| 20Weak | Inotiv, Inc. | Robert Leasure Jr. President and CEO | $4,964 16,810 shares | -1% | |
| 0Weak | Inotiv, Inc. | R Matthew Neff director | $1,771 2,000 shares | -1% | |
| 0Weak | Inotiv, Inc. | R Matthew Neff director | $2,487 2,000 shares | -1% | |
| 0Weak | Inotiv, Inc. | R Matthew Neff director | $2,858 2,000 shares | -1% | |
| 0Weak | Inotiv, Inc. | R Matthew Neff director | $3,338 2,000 shares | -1% | |
| 0Weak | Inotiv, Inc. | R Matthew Neff director | $3,818 2,000 shares | -1% | |
| 0Weak | Inotiv, Inc. | R Matthew Neff director | $3,621 2,000 shares | -1% | |
| 0Weak | Inotiv, Inc. | R Matthew Neff director | $5,246 2,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.